Primary Biliary Cholangitis Research Scholars Scientific Focus (US)

The program is designed to support any basic and translational research that addresses an unmet medical need and closes scientific gaps in the field of Primary Biliary Cholangitis (PBC) in the United States. Areas of research may include, but are not limited to:

Areas of research

Impact of other concomitant liver diseases in addition to autoimmune hepatitis and metabolic dysfunction-associated steatohepatitis (MASH)
Fibrosis progression and regression pathways
Novel biomarkers and pathways associated with symptomatology and extra hepatic manifestations including bone related diseases
Understanding epidemiology, symptomatology/Quality of LIfe (QOL), pathophysiology, pathogenesis, impact of health equity, and natural history of PBC across different racial/ethnic groups and genders
Investigation into PBC pathogenesis, including genetic predisposition and triggers for disease development
Molecular mechanisms of cholestatic pruritus
Any other basic or translational research that addresses unmet needs in PBC

Requirements

Gilead Affiliated Products

Proposals utilizing Gilead product(s) are not eligible for funding through the Research Scholars Program. Proposals involving Gilead product(s) should be submitted for review under the Investigator-Sponsored Research Grant Program through the ISR online portal.

Awards granted under the program may not be duplicative of funding from institutional or hospital, other governmental, non-governmental, or industry sources. Applicants seeking an award for research projects that are currently receiving or may receive partial funding from other sources are required to submit appropriate evidence, including budget information related to the other sources, to demonstrate that there is no direct overlap in funding.

The Research Scholars Program is intended to support independent research by emerging investigators that is unrelated to Gilead’s strategies or priorities. However, all research projects selected by the Scientific Review Committee will need to be approved by an internal validation committee that, in rare circumstances, may be unable to support certain clinical interventional studies (e.g., studies focused solely on the safety and/or efficacy of non-Gilead products).

Proposals are reviewed by an independent Scientific Review Committee, (no Commercial involvement in review or selection, i.e., Marketing, Sales, and Commercial Strategy), and are reviewed based upon the criteria outlined on this website.

View Application Essentials to discover specific application details.

Application Essentials

Is the RSP award funded by the Gilead Foundation or the "For-Profit Company"?

The award is an industry sponsored award funded by Gilead Sciences, Inc. which is a for profit entity, not the Gilead Foundation. While the award is funded by Gilead Sciences, Inc., the review of the applications and selection of awardees is carried out by an independent scientific review committee. Gilead is not part of the scientific review committee and has no involvement in selecting the applications that receive the awards.

Does the stated approximate protected time need to be specific to this award, or can it be for research in general?

The approximate protected time refers to time spent on research in general. This time does not need to be spent only on research related to your RSP proposal.

Can I share the focus of my proposal to ensure the subject is something that would be appealing to the RSP committee for funding?

The approximate protected time refers to time spent on research in general. This time does not need to be spent only on research related to your RSP proposal.